Results 111 to 120 of about 901 (171)
Cobicistat/darunavir/cobicistat/darunavir/emtricitabine/tenofovir-alafenamide/darunavir/ritonavir [PDF]
Reactions Weekly, 2020 openaire +1 more source
Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial [PDF]
Lung Cancer, 2022 Introduction: Exposure to osimertinib, a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for treatment of non-small cell lung cancer (NSCLC) and a sensitizing EGFR mutation, can be substantially below average.
Ard Van Veelen +2 more
exaly +2 more sources
Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers
Journal of Antimicrobial Chemotherapy, 2019 Background:Dolutegravir combined with darunavir/cobicistat is a promising NRTI-sparing and/or salvage strategy for the treatment of HIV-1 infection.
Emilie R Elliot +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Cobicistat, a pharmacoenhancer for HIV treatments
Drugs of Today, 2013Cobicistat is a novel cytochrome P450 3A4 (CYP3A4) inhibitor in advanced clinical evaluation for use as a pharmacoenhancer of antiretroviral drugs. It lacks significant anti-HIV activity and is more selective than ritonavir in its enzyme inhibition. In addition, its water solubility may lend itself to coformulation with other drugs.
openaire +2 more sources
Darunavir/cobicistat once daily for the treatment of HIV
Expert Review of Anti-infective Therapy, 2015A current focus in HIV management is improving adherence by minimizing pill burden with convenient formulations, including fixed-dose combinations (FDCs). Darunavir, a HIV protease inhibitor, co-administered with low-dose ritonavir (800/100 mg once daily), is recommended in guidelines in combination with other antiretrovirals for HIV patients with no ...
Thomas N, Kakuda +7 more
openaire +2 more sources
Cobicistat: a new opportunity in the treatment of HIV disease?
Expert Opinion on Pharmacotherapy, 2014Cobicistat (Cobi), a selective novel CYP3A4 inhibitor, is an orally administered, non-antiretroviral pharmacokinetic enhancer which boosts the plasma levels of several drugs, including HIV-1 protease inhibitors and the integrase strand transfer inhibitor elvitegravir (ELV).PubMed and www.clinicaltrials.gov were searched with the term 'cobicistat' for ...
Amedeo, Capetti, Giuliano, Rizzardini
openaire +2 more sources
Ritonavir and cobicistat as pharmacokinetic enhancers in pregnant women
Expert Opinion on Drug Metabolism & Toxicology, 2019Ritonavir and cobicistat are commonly used as pharmacokinetic enhancers to boost plasma concentrations of antiretrovirals used to treat HIV infection, including the protease inhibitors atazanavir, ...
Ahizechukwu C, Eke, Mark, Mirochnick
openaire +2 more sources
Rezolsta® (Darunavir/Cobicistat): First Boosted Protease Inhibitor Co-formulated with Cobicistat.
AIDS reviews, 2016Rezolsta® (darunavir/cobicistat) is the first boosted protease inhibitor in a fixed-dose combination to be approved for the treatment of HIV infection. It contains darunavir, a protease inhibitor with a well-known safety and efficacy profile, and the new pharmacokinetic enhancer cobicistat.
Adrián, Curran +2 more
openaire +1 more source
Atazanavir sulfate + cobicistat for the treatment of HIV infection
Expert Review of Anti-infective Therapy, 2017During last two decades several drugs were developed to offer long-term benefits in terms of virologic efficacy, favourable tolerability and toxicity profiles in treatment of HIV infection. Pharmacokinetics boosting of protease inhibitor allows a higher genetic barrier, as few or no drug-resistant mutations are detected in patients with virologic ...
openaire +2 more sources